Arctic Bioscience AS (OSL:ABS) Debt-to-Equity : 0.01 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS Debt-to-Equity?

Arctic Bioscience AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Arctic Bioscience AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr1.77 Mil. Arctic Bioscience AS's Total Stockholders Equity for the quarter that ended in Jun. 2024 was kr235.09 Mil. Arctic Bioscience AS's debt to equity for the quarter that ended in Jun. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Arctic Bioscience AS's Debt-to-Equity or its related term are showing as below:

OSL:ABS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.55
Current: 0.01

During the past 6 years, the highest Debt-to-Equity Ratio of Arctic Bioscience AS was 0.55. The lowest was 0.00. And the median was 0.02.

OSL:ABS's Debt-to-Equity is ranked better than
99.9% of 1016 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSL:ABS: 0.01

Arctic Bioscience AS Debt-to-Equity Historical Data

The historical data trend for Arctic Bioscience AS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS Debt-to-Equity Chart

Arctic Bioscience AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.12

0.15

0.02

Arctic Bioscience AS Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial						-	-	0.02	0.02	0.01

Competitive Comparison of Arctic Bioscience AS's Debt-to-Equity

For the Biotechnology subindustry, Arctic Bioscience AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arctic Bioscience AS's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Arctic Bioscience AS's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Arctic Bioscience AS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Arctic Bioscience AS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.531	+	2.049)	/	258.557
	=	0.02

Arctic Bioscience AS's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1.767)	/	235.094
	=	0.01

Arctic Bioscience AS (OSL:ABS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Arctic Bioscience AS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Arctic Bioscience AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

9TD:Germany

Address

Industrivegen 42, Orsta, NOR, 6155

Website

https://www.arctic-bioscience.com

Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand. The company operates in Norway, Europe, Australia and APAC.

Arctic Bioscience AS Headlines

No Headlines